The Food and Drug Administration is expected to lift restrictions on peptides that prevent compounding pharmacies from manufacturing and selling these products, according to recent reports. The move would reverse a 2023 decision that removed peptides from the agency's list of approved compounds for pharmacy production.

Health Secretary Robert F. Kennedy Jr. indicated last month that his agency would soon authorize compounding pharmacies to resume making peptide products. The announcement has generated significant interest in the wellness industry, where peptides have gained popularity among consumers seeking health and longevity benefits.

Peptides are short chains of amino acids that occur naturally in the body and play various biological roles. The compounds have experienced a surge in commercial interest, with manufacturers increasingly marketing them as supplements that may provide anti-aging and wellness benefits.

The FDA's 2023 restriction effectively prohibited compounding pharmacies from producing peptide formulations, citing regulatory concerns. Compounding pharmacies create customized medications by combining or altering ingredients to meet specific patient needs, operating under different guidelines than traditional pharmaceutical manufacturers.

The anticipated policy reversal comes despite what industry observers describe as limited scientific data supporting many of the health claims associated with peptide supplements. The wellness market has embraced these products even as researchers continue studying their efficacy and safety profiles.

The timing and specific details of the FDA's expected announcement have not been officially confirmed by the agency.